---
title: "Ulixacaltamide in Essential tremor: Terms and abbreviations"
description: "Formulary evidence on Ulixacaltamide in Essential tremor: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ulixacaltamide in Essential tremor: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| ADL | Activities of daily living |
| AHFS | American Hospital Formulary Service |
| CGI-S | Clinical Global Impression of Severity |
| CI | Confidence interval |
| CTC | Cerebello-thalamo-cortical |
| DBS | Deep brain stimulation |
| ET | Essential tremor |
| FDA | Food and Drug Administration |
| HCC | Healthcare costs |
| HCl | Hydrochloride |
| IDMC | Independent Data Monitoring Committee |
| ITT | Intention-to-treat |
| mADL | Modified activities of daily living |
| mADL11 | Modified activities of daily living scale comprising 11 items |
| MDC | Minimum detectable change |
| MDS | International Parkinson and Movement Disorder Society |
| mITT | Modified intention-to-treat |
| MMRM | Mixed model for repeated measures |
| MRI | Magnetic resonance imaging |
| MSD | Meaningful score difference |
| NDA | New Drug Application |
| NREM | Non-rapid eye movement |
| OR | Odds ratio |
| PD | Pharmacodynamics |
| PDUFA | Prescription Drug User Fee Act |
| PGI-C | Patient Global Impression of Change |
| PK | Pharmacokinetics |
| PPPY | Per patient per year |
| QD | Once daily |
| RW | Randomized withdrawal |
| SD | Standard deviation |
| TEAE | Treatment-emergent adverse event |
| TETRAS | The Essential Tremor Rating Assessment Scale |
| TETRAS-ADL | TETRAS Activities of Daily Living subscale |
| TETRAS-PRO | TETRAS patient-reported outcome measure |
| TETRAS-UL | TETRAS upper limb score |
| US | United States |

## Related pages
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor.md)
- [Ulixacaltamide: Essential tremor](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/executive-summary.md)
- [Ulixacaltamide in Essential tremor: Product information and disease description](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description.md)
- [Ulixacaltamide in Essential tremor: Clinical evidence](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence.md)
- [Ulixacaltamide in Essential tremor: Economic information and modeling report](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economics.md)
- [Ulixacaltamide in Essential tremor: References](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references.md)
- [Ulixacaltamide in Essential tremor: prevalence by geography](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/prevalence.md)
- [Ulixacaltamide in Essential tremor: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/cost-effectiveness-analyses.md)
